LEN vs PODD · rev $34.19B vs P/E 34, rev $2.07B
LEN (LEN) versus Insulet Corporation (PODD) — a side-by-side from cached financials, not a winner call.
LEN (LEN) common stock.
Insulet Corporation (PODD) is a medical devices company listed on NASDAQ.
Latest reported LEN revenue for 2025-11-30 was $34.19B. Net income was $2.08B. Revenue was down 3.5% from 2024-11-30 to 2025-11-30. LEN currently screens at market cap $0.
Latest reported PODD revenue for 2024-12-31 was $2.07B. Net income was $418.3M. Revenue was up 22.1% from 2023-12-31 to 2024-12-31. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
LEN currently screens at market cap $0. PODD currently screens at market cap $9.94B and trailing P/E 33.5.
Not investment advice. Open the LEN and PODD stock pages for the full models.
Not investment advice.